<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PENTAMIDINE ISOETHIONATE</span><br/>(pen-tam'i-deen)<br/><span class="topboxtradename">Nebupent, </span><span class="topboxtradename">Pentacarinat <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Pentam 300<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiprotozoal</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>300 mg injection; 300 mg aerosol</p>
<h1><a name="action">Actions</a></h1>
<p>Aromatic diamide antiprotozoal drug. Action mechanism is unclear, but drug appears to block parasite reproduction by interfering
         with nucleotide (DNA, RNA), phospholipid, and protein synthesis. Effective against the sporozoan parasite, <i>Pneumocystis carinii</i>. Pentamidine also has trypanosomicidal and leishmanicidal activity, but required doses for these conditions are quite toxic.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The parasite, <i>Pneumocystis carinii,</i> rarely causes infection in the general population, but if the patient is immunocompromised (e.g., AIDS) it can be fatal.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>
<i>P. carinii</i> pneumonia (PCP).
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>African trypanosomiasis and visceral leishmaniasis. (Drug supplied for the latter uses is through the Centers for Disease
         Control and Prevention, Atlanta, GA.)
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Pregnancy (category C) and lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypertension, hypotension; hyperglycemia; hypoglycemia; hypocalcemia; blood dyscrasias; liver or kidney dysfunction; diabetes
         mellitus.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Treatment of <i>Pneumocystis carinii</i> Pneumonia</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IM/IV</span> 4 mg/kg once/d for 1421 d; infuse IV over 60 min<br/><br/><span class="indicationtitle">Prophylaxis of <i>Pneumocystis carinii</i> Pneumonia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Inhaled</span> 300 mg per nebulizer q4wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Inhaled</span><br/><ul>
<li>Reconstitute contents of one vial in 6 mL sterile water (not saline) and administer using nebulizer.</li>
<li>Do not mix with any other drug.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Dissolve contents of 1 vial (300 mg) in 3 mL sterile water for injection.</li>
<li>Give deep IM into a large muscle.</li>
<li>The IM injection is painful and frequently causes local reactions (pain, indurations, swelling). Select alternate sites for
            daily doses and institute local treatment if indicated.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> IV Infusion:</span>  Dissolve contents of 1 vial in 35 mL sterile water for injection or D5W. Further dilute in 50250 mL of D5W.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span>  Give over 60 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Y-site:</span>
<b>Aldesleukin,</b>
<span class="classification">cephalosporins</span>, <b>foscarnet,</b>
<b>fluconazole.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>
            				Note: IV solutions are stable at room temperature for up to 24 h. Protect solution from light.
            			
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Confusion, hallucinations, neuralgia, dizziness, sweating. <span class="typehead">CV:</span>
<span class="speceff-life">Sudden, severe hypotension</span>, cardiac arrhythmias, ventricular tachycardia, phlebitis. <span class="typehead">GI:</span> Anorexia, nausea, vomiting, pancreatitis, unpleasant taste. <span class="typehead">Urogenital:</span>
<span class="speceff-life">Acute kidney failure</span>. <span class="typehead">Hematologic:</span> Leukopenia, thrombocytopenia, anemia. <span class="typehead">Metabolic:</span>
<span class="speceff-life">Hypoglycemia</span>, hypocalcemia, <span class="speceff-common">hyperkalemia.</span>
<span class="typehead">Respiratory:</span>
<span class="speceff-common">Cough, bronchospasm,</span> laryngitis, shortness of breath, chest pain, <span class="speceff-life">pneumothorax</span>. <span class="typehead">Skin:</span> Stevens-Johnson syndrome, facial flush (with IV injection), <span class="speceff-common">local reactions at injection site.</span>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">aminoglycosides</span>, <b>amphotericin B,</b>
<b>cidofovir,</b>
<b>cisplatin,</b>
<b>ganciclovir,</b>
<b>cyclosporine,</b>
<b>vancomycin,</b> other nephrotoxic drugs increase risk of nephrotoxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed after IM injection. <span class="typehead">Distribution:</span> Leaves bloodstream rapidly to bind extensively to body tissues. <span class="typehead">Elimination:</span> 5066% excreted in urine within 6 h; small amounts found in urine for as long as 68 wk. <span class="typehead">Half-Life:</span> 6.513.2 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP closely. Sudden severe hypotension may develop after a single dose. Place patient in supine position while receiving
            the drug. Monitor BP and HR continuously during the infusion, every half hour for 2 h thereafter, and then every 4 h until
            BP stabilizes.
         </li>
<li>Lab tests: Monitor periodically serum electrolytes, renal function, CBC with differential, platelet count, and blood glucose.</li>
<li>Measure and record I&amp;O ratio and pattern and check patient's pulse (to detect arrhythmia) at least twice daily.</li>
<li>Be alert and report promptly S&amp;S of impending kidney dysfunction (e.g., changed I&amp;O ratio, oliguria, edema). Dosage adjustment
            is indicated in renal failure.
         </li>
<li>Characteristics of pneumonia in the immunocompromised patient include constant fever, scanty (if any) sputum, dyspnea, tachypnea,
            and cyanosis.
         </li>
<li>Monitor temperature changes and institute measures to lower the temperature as indicated. Fever is a constant symptom in <i>P. carinii</i> pneumonia, but may be rapidly elevated [as high as 40° C (104° F)] shortly after drug infusion.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly to physician increasing respiratory difficulty.</li>
<li>Monitor blood glucose for loss of glycemic control if diabetic.</li>
<li>Report any unusual bruising or bleeding. Avoid using aspirin or other NSAIDs.</li>
<li>Increase fluid intake (if not contraindicated) to 23 quarts (liters) per day.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>